• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patie

Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patie

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户：wanwan1985
【摘 要】
：
Background: Previous analyses report the impact of erythropoiesis-stimulating agents (ESAs) on health-related quality of life across various populations.In this analysis, we review published studies a
【作 者】
：
Shravanthi R.Gandra Fredric O.Finkelstein Antonia V.Bennett Eldrin F.Lewis Tracy Brazg Mona L.Martin 
【机 构】
：
Amgen Inc, Thousand Oaks, CA Hospital of St.Rapha
【出 处】
：
2013年中国肾性贫血治疗专家共识研讨会
【发表日期】
：
2012年12期
【关键词】
：
Nondialysis chronic kidney disease erythropoiesis-stimulating agents energy phys 
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background: Previous analyses report the impact of erythropoiesis-stimulating agents (ESAs) on health-related quality of life across various populations.In this analysis, we review published studies and quantify the effect of ESA therapy on energy/fatigue and physical function in nondialysis patients with chronic kidney disease (CKD) related anemia.
其他文献
Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and
Sodium ferric gluconate complex in hemodialysis patients:Adverse reactions compared to placebo and iron dextran.Background.Parenteral iron is often required by hemodialysis patients to maintain adequa
会议
anaphylactoid reactionsDeclaration of Helsinkiiron deficiencyhemodialysisiro
Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who
会议
Hypersensitivity reactions and deaths associated with intravenous iron preparations
Background.Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease.Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans
会议
hypersensitivity reactionsintravenous ironiron dextraniron sucrosesodium fer
Iron Storage Indices: Novel Predictors of Bacteremia in Hemodialysis Patients Initiating Intravenous
Bacterial sepsis is the second leading cause of death among hemodialysis (HD) patients.Iron overload and intravenous iron therapy are linked to bacterial infection.This study examined iron stores, int
会议
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.Background.Iron is essential for the formation of hemoglobin.During long-term treatment with human recombinant ery
会议
ironchronic kidney failureneutrophilsrandomized controlled trial
Optimal Treatment of Renal Anaemia (OPTA): improving the efficacy and efficiency of renal anaemia th
The medical care of renal anaemia has received much attention over the past decade, as nephrologists have recognized the increased therapeutic value of erythropoiesis-stimulating agents.The European B
会议
epoetinhaemodialysisinfectioninflammationironrenal anaemia
Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disea
Background and objectives: Optimal hemoglobin targets for chronic kidney disease patients receiving erythropoiesisstimulating agents remain controversial.The effects of different hemoglobin targets on
会议
Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure
Background.Intravenous iron is a recognized therapy of anaemia in chronic haemodialyzed patients,especially in those receiving erythropoietin (Epo),while its role in the anaemia of pre-dialyzed chroni
会议
anaemiachronic renal failureiron therapypre-dialysis
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline upd
Purpose: To update American Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.Methods: AnUpdate Co
会议
American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Upd
Purpose To update American Society of Clinical Oncology/American Society of Hematology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.Methods An Update Com
会议